publication venue for
- High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils.. 13. 2024
- Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases.. 12. 2023
- CD40 agonism improves anti-tumor T cell priming induced by the combination of radiation therapy plus CTLA4 inhibition and enhances tumor response.. 12. 2023
- Stem cell-like T cell depletion in the recurrent head and neck cancer immune microenvironment.. 12. 2023
- Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses.. 11. 2022
- Tumor-associated macrophages promote intratumoral conversion of conventional CD4+ T cells into regulatory T cells via PD-1 signalling.. 11. 2022
- Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes.. 11. 2022
- LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.. 10. 2021
- Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy.. 10. 2021
- A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.. 10. 2021
- A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy.. 10. 2021
- Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer.. 9. 2020
- Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.. 9. 2020
- Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.. 9. 2020
- Targeting ubiquitin protein ligase E3 component N-recognin 5 in cancer cells induces a CD8+ T cell mediated immune response.. 9. 2020
- Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy.. 9. 2020
- Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery.. 8. 2019
- Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.. 8. 2019
- Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.. 8. 2019
- Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer.. 8. 2019
- Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells.. 8. 2019
- Clinical characterization of colitis arising from anti-PD-1 based therapy.. 8. 2018
- Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.. 8. 2018
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.. 7. 2018
- Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.. 7. 2018
- CD4+ Th1 to the rescue in HER-2+ breast cancer.. 8. 2018
- Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer.. 7. 2018
- Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.. 7. 2018
- Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.. 7. 2017
- Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.. 6. 2017
- Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages.. 6. 2017
- Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.. 6. 2017
- Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling.. 6. 2017
- Maternal microchimerism is prevalent in cord blood in memory T cells and other cell subsets, and persists post-transplant.. 6. 2017
- Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.. 6. 2017
- Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer.. 6. 2016
- CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy.. 6. 2016
- An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.. 6. 2016
- Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.. 5. 2016
- IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay.. 5. 2016
- Dectin-1-activated dendritic cells: A potent Th9 cell inducer for tumor immunotherapy.. 5. 2016
- Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.. 5. 2016
- Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ERpos/HER2pos early breast cancer.. 6. 2016
- IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression.. 6. 2016
- Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.. 5. 2016
- Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.. 5. 2016
- Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy.. 5. 2015
- Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).. 4. 2015
- Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.. 4. 2015
- Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.. 4. 2015
- Genetics and immunology: reinvigorated.. 4. 2015
- Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.. 4. 2015
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.. 4. 2015
- Immune independent crosstalk between lymphoma and myeloid suppressor CD14+HLA-DRlow/neg monocytes mediates chemotherapy resistance.. 4. 2015
- IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.. 4. 2015
- The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer.. 3. 2014
- Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy.. 3. 2014
- Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.. 3. 2014
- Is tumor (R)ejection by the immune system the "5th R" of radiobiology?. 3. 2014
- Detection of cancer/testis antigens as a diagnostic tool in routine pathology practice.. 3. 2014
- The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer.. 2. 2013
- Prognostic value of the immune microenvironment in lung adenocarcinoma.. 2. 2013
- Approaching untargetable tumor-associated antigens with antibodies.. 2. 2013
- Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma.. 2. 2013
- Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment.. 2. 2013
- Utilizing TH9 cells as a novel therapeutic strategy for malignancies.. 2. 2013
- Myeloid-derived suppressor sells and the efficacy of CD8+ T-cell immunotherapy.. 2. 2013
- How do CARs work?: Early insights from recent clinical studies targeting CD19.. 1. 2012
- "Flagellated" cancer cells propel anti-tumor immunity.. 1. 2012
- Good things come in small packages: Therapeutic anti-tumor immunity induced by microRNA nanoparticles.. 1. 2012
- DKK1 as a novel target for myeloma immunotherapy.. 1. 2012
- Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo.. 1. 2012
- Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. 2024
- CARs on a highway with roadblocks.. 6. 2017
- CD103+ cells at the forefront of anticancer immunity.. 6. 2017
- PD-L1 blockade for urothelial carcinoma.. 6. 2017
- Activin A backs-up TGF-ß to promote regulatory T cells. 2021
- IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection. 2020
- Trial watch: Immune checkpoint blockers for cancer therapy. 2017
- Trial Watch: Immunotherapy plus radiation therapy for oncological indications. 2016
- Prioritization schema for immunotherapy clinical trials in glioblastoma. 2016
- T cell receptor mimic antibodies for cancer therapy. 2015
- Consensus guidelines for the detection of immunogenic cell death. 2014
- Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. 2023